Suppr超能文献

一例因基因()罕见点突变被诊断为Leber遗传性视神经病变患者出现自发性视力恢复的典型病例报告及文献复习

A Typical Case Presentation with Spontaneous Visual Recovery in Patient Diagnosed with Leber Hereditary Optic Neuropathy due to Rare Point Mutation in Gene () and Literature Review.

作者信息

Liutkeviciene Rasa, Sidaraite Agne, Kuliaviene Lina, Glebauskiene Brigita, Jurkute Neringa, Aluzaite-Baranauskiene Lina, Gelzinis Arvydas, Zemaitiene Reda

机构信息

Department of Ophthalmology, Lithuanian University of Health Sciences, Medical Academy, Eiveniu 2 str., Kaunas LT-50161, Lithuania.

Neuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Eiveniu str. 2, Kaunas LT-50161, Lithuania.

出版信息

Medicina (Kaunas). 2021 Feb 26;57(3):202. doi: 10.3390/medicina57030202.

Abstract

Leber hereditary optic neuropathy (LHON) is one of the most common inherited mitochondrial optic neuropathies, caused by mitochondrial DNA (mtDNA) mutations. Three most common mutations, namely , and , account for the majority of LHON cases. These mutations lead to mitochondrial respiratory chain complex I damage. Typically, LHON presents at the 15-35 years of age with male predominance. LHON is associated with severe, subacute, painless bilateral vision loss and account for one of the most common causes of legal blindness in young individuals. Spontaneous visual acuity recovery is rare and has been reported in patients harbouring mutation. Up to date LHON treatment is limited. Idebenone has been approved by European Medicines Agency (EMA) to treat LHON. However better understanding of disease mechanisms and ongoing treatment trials are promising and brings hope for patients. In this article we report on a patient diagnosed with LHON harbouring rare mutation in gene, who experienced spontaneous visual recovery. In addition, we summarise clinical presentation, diagnostic features, and treatment.

摘要

Leber遗传性视神经病变(LHON)是最常见的遗传性线粒体视神经病变之一,由线粒体DNA(mtDNA)突变引起。三种最常见的突变,即 、 和 ,占LHON病例的大多数。这些突变导致线粒体呼吸链复合体I受损。通常,LHON发病年龄在15至35岁,男性居多。LHON与严重、亚急性、无痛性双侧视力丧失有关,是年轻个体法定失明的最常见原因之一。自发视力恢复很少见,有报道称携带 突变的患者会出现这种情况。到目前为止,LHON的治疗方法有限。艾地苯醌已获欧洲药品管理局(EMA)批准用于治疗LHON。然而,对疾病机制的深入了解以及正在进行的治疗试验前景乐观,为患者带来了希望。在本文中,我们报告了一名被诊断为LHON的患者,其 基因存在罕见的 突变,该患者经历了自发视力恢复。此外,我们总结了临床表现、诊断特征和治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6313/7996816/96ff338ee820/medicina-57-00202-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验